PubMed Health⌕ Search

Biomedical subjects

F Ferrer

Publications and source records attributed to F Ferrer.

44 records · Page 3Linked to original sources

[Physiopathology of hemostasis. Which advances are useful for the clinician?].

Progress made in the field of haemostasis 30 years ago was essentially to do with the identification of the different activators of coagulation, the deficits of which provoke hemorrhage. Over the last ten years, progress has been made which is of benefit to research into thrombosis. This wave of progress, still in its infancy, aids both the understanding of the mechanisms involved, and the treatment of thrombosis. The role of the deficits reducing coagulation in the occurrence of thromboses is the most distinctive if not unique, fact. The molecular study of the factors of coagulation constitutes another aspect of recent progress; this gives a better understanding of the pathological phenomena and anticoagulant behaviour. Examples are given of this progress in molecular study and in the aetiological diagnosis of thrombosis.

Antithrombin III↗

[Clinical problems posed by the consumption of antithrombin III induced by heparin].

Two cases of resistance to the heparin treatment, induced by large consumption of antithrombin III, are reported. Normally small, this consumption does not automatically call for the systematic dosage of Antithrombin III for each treatment using heparin. On the other hand, any clinical or biological resistance to higher doses of heparin, any personal or family history of thrombosis necessitate the administration of Antithrombin III. Where there is an acquired or congenital deficit, an injection of Antithrombin III corrects the disorder and reduces the risk of thrombosis. In the case of a heparin-antivitamin K relay, it is essential to achieve complete biological effectiveness of the antivitamins K to interrupt the administration of the heparin.

Adult↗

[Familial recurrent phlebitis due to deficiency of antithrombin III. Apropos of a case].

The authors report the case of a young woman aged 29, mother of 2 children, presenting a post-phlebitic syndrome with hyperalgic capillaritic ulcer, a 10 year history of serious thrombophlebitic episodes with repeated pulmonary embolism despite heparin therapy, and reports of similar episodes in the family, some of which proved fatal. Haematological study showed a clear diminution in progressive antithrombin activity. A discussion follows on the clinical and haematological aspects of this constitutional and familial deficiency, which has been known since 1965 (Egelberg). The relative rarity of this condition should not prevent the routine search (by combined functional, immunological and chromogenic estimation) in the presence of repeated thrombosis, and when the thrombosis is biologically resistant to heparin : in such cases, the indication for long term treatment with vitamin K antagonists is undeniable.

Adult↗

Differences in phycoerythrin- or fluorescein-isothiocyanate conjugated 8G12 on CD34+ cell evaluation.

To evaluate the equivalence of 8G12 conjugated with either phycoerythrin (PE) or fluorescein isothiocyanate (FITC), duplicate fluorochrome-8G12 labelling was carried out in 229 samples. Additionally, 53 samples were simultaneously immunostained with FITC-8G12 and PE-8G12. Significantly higher values (p < 0.001) were observed in PE-CD34+ cells when compared with FITC-CD34+ cells both in duplicate and simultaneous analysis. Our data suggest that the choice of fluorochrome is relevant in the measurement of CD34+ cells with 8G12.

Antibodies, Monoclonal↗

[Otoneurological manifestations of basilar dolicoectasia. A report of six cases].

Megadolichobasilar is a vascular anomaly consisting of widening and elongation of the basilar artery. It is rare and may produce otoneurological manifestations such as vertigo, sudden deafness, trigeminal neuralgia, and facial spasm or palsy. Six cases of megadolichobasilar diagnosed by magnetic resonance angiography are reported and their pathogenesis is discussed.

Adult↗

A comparative study of two third-generation anti-hepatitis C virus ELISAs.

The sensitivity and specificity of two third-generation screening tests for the detection of antibody to hepatitis C virus (anti-HCV) was evaluated in a side-by-side study (Abbott HCV EIA 3.0/Ortho HCV ELISA 3.0). Specimens that were reactive in either ELISA were then retested by the other ELISA, and confirmed by RIBA-3. The screening of 15,540 serum samples from healthy blood donors showed a significantly lower number of reactive cases tested by Ortho (21 out of 8,805, 0.24%), than tested by Abbott (35 out of 6,735, 0.52%). In the side-by-side comparison, we found that significantly (p = 0.005) more Ortho-positive samples were also reactive in Abbott (14/21, 66.6%), than in Abbott followed by Ortho (7/35, 20%). Moreover, the RIBA analysis revealed a significantly (p = 0.014) higher number of RIBA-positive specimens among those reactive in Ortho 10/21 (47.6%), than among those reactive in Abbott 6/35 (17.2%), thus the former provides a greater positive predictive value. However, we did not observed differences in the sensitivity between Abbott and Ortho, because all RIBA-positive samples demonstrated reactivity in both ELISAs.

Blood Donors↗